Is CTNM or UNCY more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Contineum Therapeutics N/A -27.09% -25.64% Unicycive Therapeutics N/A -134.69% -84.51%

Does the media favor CTNM or UNCY?

In the previous week, Unicycive Therapeutics had 7 more articles in the media than Contineum Therapeutics. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Unicycive Therapeutics' score of -0.10 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to UNCY or ARVN?

In the previous week, Unicycive Therapeutics had 7 more articles in the media than Arvinas. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat Unicycive Therapeutics' score of -0.10 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Arvinas 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is UNCY or NGNE more profitable?

Neurogene's return on equity of -37.88% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Neurogene N/A -37.88% -34.70%

Does the media refer more to UNCY or NGNE?

In the previous week, Unicycive Therapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 6 mentions for Neurogene. Neurogene's average media sentiment score of 0.33 beat Unicycive Therapeutics' score of -0.10 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Neurogene 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is UNCY or STTK more profitable?

Shattuck Labs' return on equity of -60.73% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Shattuck Labs N/A -60.73% -55.75%

Does the media refer more to UNCY or STTK?

In the previous week, Unicycive Therapeutics had 4 more articles in the media than Shattuck Labs. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.45 beat Unicycive Therapeutics' score of -0.10 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Unicycive Therapeutics (UNCY) Competitors

$5.09 -0.12 (-2.30%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$5.08 -0.01 (-0.29%)

As of 07:18 AM Eastern

Compare

UNCY vs. CTNM, ARVN, AQST, NGNE, and STTK

Should you buy Unicycive Therapeutics stock or one of its competitors? MarketBeat compares Unicycive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Unicycive Therapeutics include Contineum Therapeutics (CTNM), Arvinas (ARVN), Aquestive Therapeutics (AQST), Neurogene (NGNE), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry.

How does Unicycive Therapeutics compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Contineum Therapeutics' return on equity of -27.09% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Contineum Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

40.4% of Unicycive Therapeutics shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Contineum Therapeutics presently has a consensus target price of $20.00, indicating a potential upside of 36.80%. Unicycive Therapeutics has a consensus target price of $21.75, indicating a potential upside of 327.31%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Unicycive Therapeutics has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	10.93	-$59.98M	-$1.95	N/A
Unicycive Therapeutics	$680K	205.02	-$26.56M	-$2.21	N/A

In the previous week, Unicycive Therapeutics had 7 more articles in the media than Contineum Therapeutics. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Unicycive Therapeutics' score of -0.10 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Unicycive Therapeutics beats Contineum Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Arvinas?

Unicycive Therapeutics (NASDAQ:UNCY) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

Unicycive Therapeutics has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	205.02	-$26.56M	-$2.21	N/A
Arvinas	$262.60M	1.99	-$80.80M	-$3.32	N/A

In the previous week, Unicycive Therapeutics had 7 more articles in the media than Arvinas. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.89 beat Unicycive Therapeutics' score of -0.10 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Arvinas	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Unicycive Therapeutics currently has a consensus price target of $21.75, suggesting a potential upside of 327.31%. Arvinas has a consensus price target of $15.42, suggesting a potential upside of 90.33%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Unicycive Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Arvinas	-247.54%	-44.38%	-28.38%

Summary

Unicycive Therapeutics beats Arvinas on 9 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Aquestive Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 109.36%. Unicycive Therapeutics has a consensus price target of $21.75, suggesting a potential upside of 327.31%. Given Unicycive Therapeutics' higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Unicycive Therapeutics has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.44	-$83.78M	-$0.61	N/A
Unicycive Therapeutics	$680K	205.02	-$26.56M	-$2.21	N/A

In the previous week, Unicycive Therapeutics had 8 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.93 beat Unicycive Therapeutics' score of -0.10 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aquestive Therapeutics	Positive
Unicycive Therapeutics	Neutral

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Unicycive Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Aquestive Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Summary

Unicycive Therapeutics beats Aquestive Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Neurogene?

Unicycive Therapeutics (NASDAQ:UNCY) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Unicycive Therapeutics currently has a consensus target price of $21.75, indicating a potential upside of 327.31%. Neurogene has a consensus target price of $84.83, indicating a potential upside of 121.38%. Given Unicycive Therapeutics' higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Unicycive Therapeutics has higher earnings, but lower revenue than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	205.02	-$26.56M	-$2.21	N/A
Neurogene	$930K	651.03	-$90.35M	-$4.55	N/A

In the previous week, Unicycive Therapeutics had 3 more articles in the media than Neurogene. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 6 mentions for Neurogene. Neurogene's average media sentiment score of 0.33 beat Unicycive Therapeutics' score of -0.10 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Neurogene	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene's return on equity of -37.88% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Neurogene	N/A	-37.88%	-34.70%

Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Summary

Neurogene beats Unicycive Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Shattuck Labs?

Unicycive Therapeutics (NASDAQ:UNCY) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Unicycive Therapeutics had 4 more articles in the media than Shattuck Labs. MarketBeat recorded 9 mentions for Unicycive Therapeutics and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.45 beat Unicycive Therapeutics' score of -0.10 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Unicycive Therapeutics has higher earnings, but lower revenue than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	205.02	-$26.56M	-$2.21	N/A
Shattuck Labs	$1M	493.05	-$48.81M	-$0.63	N/A

Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Unicycive Therapeutics currently has a consensus target price of $21.75, suggesting a potential upside of 327.31%. Shattuck Labs has a consensus target price of $11.00, suggesting a potential upside of 71.07%. Given Unicycive Therapeutics' higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Shattuck Labs' return on equity of -60.73% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Shattuck Labs	N/A	-60.73%	-55.75%

Summary

Shattuck Labs beats Unicycive Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UNCY vs. The Competition

Export

Metric	Unicycive Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$142.72M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-2.30	19.17	27.12	24.26
Price / Sales	205.02	838.79	587.25	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	3.61	4.22	10.89	6.29
Net Income	-$26.56M	$64.26M	$3.58B	$330.66M
7 Day Performance	-6.26%	-3.58%	-2.11%	-1.35%
1 Month Performance	-29.79%	2.12%	3.28%	-0.64%
1 Year Performance	4.30%	20.35%	26.33%	19.08%

Unicycive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UNCY Unicycive Therapeutics	3.0051 of 5 stars	$5.09 -2.3%	$21.75 +327.3%	+1.6%	$142.72M	$680K	N/A	9
CTNM Contineum Therapeutics	1.9634 of 5 stars	$14.56 -6.3%	$20.00 +37.4%	+273.0%	$549.07M	$50M	N/A	31	News Coverage
ARVN Arvinas	3.5427 of 5 stars	$8.46 +0.1%	$15.42 +82.3%	+4.0%	$545.65M	$262.60M	N/A	420	News Coverage Gap Up
AQST Aquestive Therapeutics	2.6852 of 5 stars	$4.29 +1.1%	$8.50 +98.4%	+1.2%	$537.64M	$44.54M	N/A	160
NGNE Neurogene	3.2063 of 5 stars	$33.86 +4.0%	$84.83 +150.5%	+78.8%	$536.30M	N/A	N/A	90	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UNCY) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. CTNM, ARVN, AQST, NGNE, and STTK

How does Unicycive Therapeutics compare to Contineum Therapeutics?

Summary

How does Unicycive Therapeutics compare to Arvinas?

Summary

How does Unicycive Therapeutics compare to Aquestive Therapeutics?

Summary

How does Unicycive Therapeutics compare to Neurogene?

Summary

How does Unicycive Therapeutics compare to Shattuck Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. CTNM, ARVN, AQST, NGNE, and STTK

How does Unicycive Therapeutics compare to Contineum Therapeutics?

Is CTNM or UNCY more profitable?

Which has more risk & volatility, CTNM or UNCY?

Do institutionals and insiders have more ownership in CTNM or UNCY?

Do analysts rate CTNM or UNCY?

Which has stronger earnings and valuation, CTNM or UNCY?

Does the media favor CTNM or UNCY?

Summary

How does Unicycive Therapeutics compare to Arvinas?

Which has more risk & volatility, UNCY or ARVN?

Which has higher earnings & valuation, UNCY or ARVN?

Does the media refer more to UNCY or ARVN?

Do analysts prefer UNCY or ARVN?

Do institutionals & insiders hold more shares of UNCY or ARVN?

Is UNCY or ARVN more profitable?

Summary

How does Unicycive Therapeutics compare to Aquestive Therapeutics?

Do analysts prefer AQST or UNCY?

Which has preferable earnings and valuation, AQST or UNCY?

Does the media favor AQST or UNCY?

Do institutionals & insiders hold more shares of AQST or UNCY?

Is AQST or UNCY more profitable?

Which has more volatility and risk, AQST or UNCY?

Summary

How does Unicycive Therapeutics compare to Neurogene?

Do insiders and institutionals have more ownership in UNCY or NGNE?

Do analysts prefer UNCY or NGNE?

Which has stronger valuation and earnings, UNCY or NGNE?

Does the media refer more to UNCY or NGNE?

Is UNCY or NGNE more profitable?

Which has more volatility and risk, UNCY or NGNE?

Summary

How does Unicycive Therapeutics compare to Shattuck Labs?

Do insiders & institutionals hold more shares of UNCY or STTK?

Does the media refer more to UNCY or STTK?

Which has better valuation & earnings, UNCY or STTK?

Which has more volatility and risk, UNCY or STTK?

Do analysts rate UNCY or STTK?

Is UNCY or STTK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools